Friedman Allon N, Wolfe Bruce
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana; and
Department of Surgery, Oregon Health and Science University, Portland, Oregon.
Clin J Am Soc Nephrol. 2016 Mar 7;11(3):528-35. doi: 10.2215/CJN.07670715. Epub 2015 Oct 8.
Type II diabetic kidney disease is devastating to patients and society alike. This review will evaluate bariatric surgery as a treatment for diabetic kidney disease primarily through its ability to induce and maintain regression of type II diabetes. The review begins by outlining the global challenge of diabetic kidney disease, its link to obesity, and the comparative benefits of bariatric surgery on weight and type II diabetes. It then surveys comprehensively the relevant literature, which reports that although bariatric surgery is associated with reductions in albuminuria, its effect on harder clinical end points like progression of diabetic kidney disease is not known. The review also includes a critical assessment of the risks and costs of bariatric surgery and concludes by acknowledging the major knowledge gaps in the field and providing research strategies to overcome them. Until these knowledge gaps are filled, clinicians will be forced to rely on their own subjective judgment in determining the benefit-risk ratio of bariatric surgery for patients with diabetic kidney disease.
II型糖尿病肾病对患者和社会都具有极大的破坏性。本综述将主要通过评估减重手术诱导和维持II型糖尿病缓解的能力,来评价其作为糖尿病肾病治疗方法的效果。综述首先概述了糖尿病肾病的全球挑战、其与肥胖的关联以及减重手术在体重和II型糖尿病方面的相对益处。接着全面审视了相关文献,这些文献表明,尽管减重手术与蛋白尿减少有关,但其对糖尿病肾病进展等更严峻的临床终点的影响尚不清楚。该综述还对减重手术的风险和成本进行了批判性评估,最后承认该领域存在的主要知识空白,并提供了克服这些空白的研究策略。在这些知识空白得到填补之前,临床医生在确定减重手术对糖尿病肾病患者的获益风险比时,将不得不依靠自己的主观判断。